HLB Life Science CO.,LTD.
067630·KOSDAQ·2 grants
- Shares granted, cumulative
- 630,000shares
- Next lockup release
- —
Against the share price
At the 2026-08-18 close- Shares with a reason to exercise
- None
- Sellable right now
- None
- Unrealized paper gain (to the employees)
- —
Potential dilution
Options the share price has risen past gain a reason to be exercised and sold once the lockup ends. Filings do not show what has already been exercised or forfeited, so these figures are on a cumulative grants basis and the shares actually outstanding may be fewer.
Recipients by role
- Unregistered officer13 people57%
- Employee23 people43%
Sorted from the relation text written in the filings (36 recipients). Officers of affiliates and subsidiaries are counted as unregistered officers.
Shares granted by year
Grant history · lockup schedule
Exercisable shares over time
It rises on the day a lockup ends and falls on the day an exercise window closes. Options actually exercised are not subtracted, because only executives have to report them.
20172 grants · 630,000 shares
- Filed 2017-12-28 · grant details not collectedDART filing
DART does not serve the source document for this filing. Check the number of shares, the strike price and the lockup release date in the DART filing itself.
[Amended] Report on grant of stock options
- Granted2017-03-03
- Exercise starts2019-03-03
- Exercise ends2021-03-02
- Shares granted
- 630,000shares
- Strike price
- 6,500KRW
- Grant method
- New share issuance
- Approved by
- Board of directors
Below the strike priceShare price below the strike — no reason to exerciseReport on grant of stock options
Every figure here is parsed mechanically from the original DART filing (document.xml). “Exercise starts (estimated)” means the filing did not state an exercise period, so the date is the grant date plus two years under Article 340-2(4) of the Korean Commercial Act and may differ from the actual terms. Always read the original filing before making any decision.